B2i Digital (@b2idigital) “eXoZymes (Nasdaq: EXOZ) (@eXoZymes) announced the pricing of a public offering e” — TopicDigg

eXoZymes (Nasdaq: EXOZ) (@eXoZymes) announced the pricing of a public offering expected to generate approximately $5.3 million in gross proceeds, with funding intended to support development of its NCT program, continued R&D, and general corporate initiatives. For investors following eXoZymes, the announcement is significant because it provides additional capital to advance the company's AI-enabled exozyme platform and its efforts to scale production of high-value molecules for nutraceutical, pharmaceutical, and specialty chemical markets. eXoZymes is focused on using engineered enzymes operating outside living cells to manufacture complex molecules at commercial scale, an approach the company believes can overcome limitations associated with traditional biomanufacturing methods. Read the full announcement: eXoZymes is a B2i Digital (@b2idigital) Featured Company. See the company’s profile at Disclosure: This post is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to purchase EXOZ or any other security. David Shapiro, CEO of B2i Digital, personally purchased shares of unrestricted EXOZ stock in the open market as part of B2i Digital's practice of investing alongside its Featured Companies. Investors should conduct their own due diligence and consult qualified financial and professional advisors before making any investment decisions.